Semaglutide Demand Surge Real, But 'Fast-Tracked Generics' Claim Requires Correction

Explosive uptake of Ozempic and Wegovy is well-supported, but patents extend into the 2030s and regulators expanded compounding access—not generic approval—during shortages.

ndtv-profit-business · 7/1/2026, 9:03:28 AM · Ask about this →